PMC:7402624 / 75188-75599 JSONTXT

{"project":"LitCovid-PD-FMA-UBERON","denotations":[{"id":"T554","span":{"begin":196,"end":198},"obj":"Body_part"},{"id":"T555","span":{"begin":209,"end":214},"obj":"Body_part"},{"id":"T556","span":{"begin":246,"end":251},"obj":"Body_part"},{"id":"T557","span":{"begin":283,"end":288},"obj":"Body_part"},{"id":"T558","span":{"begin":290,"end":293},"obj":"Body_part"},{"id":"T559","span":{"begin":327,"end":332},"obj":"Body_part"},{"id":"T560","span":{"begin":334,"end":337},"obj":"Body_part"},{"id":"T561","span":{"begin":371,"end":376},"obj":"Body_part"}],"attributes":[{"id":"A554","pred":"fma_id","subj":"T554","obj":"http://purl.org/sig/ont/fma/fma84371"},{"id":"A555","pred":"fma_id","subj":"T555","obj":"http://purl.org/sig/ont/fma/fma68646"},{"id":"A556","pred":"fma_id","subj":"T556","obj":"http://purl.org/sig/ont/fma/fma68646"},{"id":"A557","pred":"fma_id","subj":"T557","obj":"http://purl.org/sig/ont/fma/fma68646"},{"id":"A558","pred":"fma_id","subj":"T558","obj":"http://purl.org/sig/ont/fma/fma84795"},{"id":"A559","pred":"fma_id","subj":"T559","obj":"http://purl.org/sig/ont/fma/fma68646"},{"id":"A560","pred":"fma_id","subj":"T560","obj":"http://purl.org/sig/ont/fma/fma84795"},{"id":"A561","pred":"fma_id","subj":"T561","obj":"http://purl.org/sig/ont/fma/fma68646"}],"text":"Definition of immunotype 3\nTo define COVID-19 patients with low or absent immune responses, classified as immunotype 3, the intersection of the bottom 50% of 5 different flow parameters was used: PB as % of B cells, KI67+ as % of non-naïve CD4 T cells, KI67+ as % of non-naïve CD8 T cells, HLA-DR+CD38+ as % of non-naïve CD4 T cells, HLA-DR+CD38+ as % of non-naïve CD8 T cells—graphically displayed in fig. S10."}

{"project":"LitCovid-PubTator","denotations":[{"id":"2182","span":{"begin":240,"end":243},"obj":"Gene"},{"id":"2183","span":{"begin":277,"end":280},"obj":"Gene"},{"id":"2184","span":{"begin":297,"end":301},"obj":"Gene"},{"id":"2185","span":{"begin":321,"end":324},"obj":"Gene"},{"id":"2186","span":{"begin":341,"end":345},"obj":"Gene"},{"id":"2187","span":{"begin":365,"end":368},"obj":"Gene"},{"id":"2188","span":{"begin":46,"end":54},"obj":"Species"},{"id":"2189","span":{"begin":37,"end":45},"obj":"Disease"}],"attributes":[{"id":"A2182","pred":"tao:has_database_id","subj":"2182","obj":"Gene:920"},{"id":"A2183","pred":"tao:has_database_id","subj":"2183","obj":"Gene:925"},{"id":"A2184","pred":"tao:has_database_id","subj":"2184","obj":"Gene:952"},{"id":"A2185","pred":"tao:has_database_id","subj":"2185","obj":"Gene:920"},{"id":"A2186","pred":"tao:has_database_id","subj":"2186","obj":"Gene:952"},{"id":"A2187","pred":"tao:has_database_id","subj":"2187","obj":"Gene:925"},{"id":"A2188","pred":"tao:has_database_id","subj":"2188","obj":"Tax:9606"},{"id":"A2189","pred":"tao:has_database_id","subj":"2189","obj":"MESH:C000657245"}],"namespaces":[{"prefix":"Tax","uri":"https://www.ncbi.nlm.nih.gov/taxonomy/"},{"prefix":"MESH","uri":"https://id.nlm.nih.gov/mesh/"},{"prefix":"Gene","uri":"https://www.ncbi.nlm.nih.gov/gene/"},{"prefix":"CVCL","uri":"https://web.expasy.org/cellosaurus/CVCL_"}],"text":"Definition of immunotype 3\nTo define COVID-19 patients with low or absent immune responses, classified as immunotype 3, the intersection of the bottom 50% of 5 different flow parameters was used: PB as % of B cells, KI67+ as % of non-naïve CD4 T cells, KI67+ as % of non-naïve CD8 T cells, HLA-DR+CD38+ as % of non-naïve CD4 T cells, HLA-DR+CD38+ as % of non-naïve CD8 T cells—graphically displayed in fig. S10."}

{"project":"LitCovid-PD-MONDO","denotations":[{"id":"T440","span":{"begin":37,"end":45},"obj":"Disease"},{"id":"T441","span":{"begin":196,"end":198},"obj":"Disease"}],"attributes":[{"id":"A440","pred":"mondo_id","subj":"T440","obj":"http://purl.obolibrary.org/obo/MONDO_0100096"},{"id":"A441","pred":"mondo_id","subj":"T441","obj":"http://purl.obolibrary.org/obo/MONDO_0019035"}],"text":"Definition of immunotype 3\nTo define COVID-19 patients with low or absent immune responses, classified as immunotype 3, the intersection of the bottom 50% of 5 different flow parameters was used: PB as % of B cells, KI67+ as % of non-naïve CD4 T cells, KI67+ as % of non-naïve CD8 T cells, HLA-DR+CD38+ as % of non-naïve CD4 T cells, HLA-DR+CD38+ as % of non-naïve CD8 T cells—graphically displayed in fig. S10."}

{"project":"LitCovid-PD-CLO","denotations":[{"id":"T1058","span":{"begin":207,"end":214},"obj":"http://purl.obolibrary.org/obo/CL_0000236"},{"id":"T1059","span":{"begin":234,"end":251},"obj":"http://purl.obolibrary.org/obo/CL_0000895"},{"id":"T1060","span":{"begin":277,"end":280},"obj":"http://purl.obolibrary.org/obo/CLO_0053438"},{"id":"T1061","span":{"begin":281,"end":288},"obj":"http://purl.obolibrary.org/obo/CL_0000084"},{"id":"T1062","span":{"begin":297,"end":301},"obj":"http://purl.obolibrary.org/obo/PR_000001408"},{"id":"T1063","span":{"begin":315,"end":332},"obj":"http://purl.obolibrary.org/obo/CL_0000895"},{"id":"T1064","span":{"begin":341,"end":345},"obj":"http://purl.obolibrary.org/obo/PR_000001408"},{"id":"T1065","span":{"begin":365,"end":368},"obj":"http://purl.obolibrary.org/obo/CLO_0053438"},{"id":"T1066","span":{"begin":369,"end":376},"obj":"http://purl.obolibrary.org/obo/CL_0000084"}],"text":"Definition of immunotype 3\nTo define COVID-19 patients with low or absent immune responses, classified as immunotype 3, the intersection of the bottom 50% of 5 different flow parameters was used: PB as % of B cells, KI67+ as % of non-naïve CD4 T cells, KI67+ as % of non-naïve CD8 T cells, HLA-DR+CD38+ as % of non-naïve CD4 T cells, HLA-DR+CD38+ as % of non-naïve CD8 T cells—graphically displayed in fig. S10."}

{"project":"LitCovid-PD-CHEBI","denotations":[{"id":"T84888","span":{"begin":196,"end":198},"obj":"Chemical"},{"id":"T53019","span":{"begin":294,"end":296},"obj":"Chemical"},{"id":"T74745","span":{"begin":338,"end":340},"obj":"Chemical"}],"attributes":[{"id":"A11724","pred":"chebi_id","subj":"T84888","obj":"http://purl.obolibrary.org/obo/CHEBI_53319"},{"id":"A1015","pred":"chebi_id","subj":"T84888","obj":"http://purl.obolibrary.org/obo/CHEBI_60686"},{"id":"A37252","pred":"chebi_id","subj":"T53019","obj":"http://purl.obolibrary.org/obo/CHEBI_73445"},{"id":"A87424","pred":"chebi_id","subj":"T74745","obj":"http://purl.obolibrary.org/obo/CHEBI_73445"}],"text":"Definition of immunotype 3\nTo define COVID-19 patients with low or absent immune responses, classified as immunotype 3, the intersection of the bottom 50% of 5 different flow parameters was used: PB as % of B cells, KI67+ as % of non-naïve CD4 T cells, KI67+ as % of non-naïve CD8 T cells, HLA-DR+CD38+ as % of non-naïve CD4 T cells, HLA-DR+CD38+ as % of non-naïve CD8 T cells—graphically displayed in fig. S10."}

{"project":"LitCovid-PD-GO-BP","denotations":[{"id":"T136","span":{"begin":74,"end":90},"obj":"http://purl.obolibrary.org/obo/GO_0006955"}],"text":"Definition of immunotype 3\nTo define COVID-19 patients with low or absent immune responses, classified as immunotype 3, the intersection of the bottom 50% of 5 different flow parameters was used: PB as % of B cells, KI67+ as % of non-naïve CD4 T cells, KI67+ as % of non-naïve CD8 T cells, HLA-DR+CD38+ as % of non-naïve CD4 T cells, HLA-DR+CD38+ as % of non-naïve CD8 T cells—graphically displayed in fig. S10."}

{"project":"LitCovid-sentences","denotations":[{"id":"T465","span":{"begin":0,"end":26},"obj":"Sentence"},{"id":"T466","span":{"begin":27,"end":411},"obj":"Sentence"}],"namespaces":[{"prefix":"_base","uri":"http://pubannotation.org/ontology/tao.owl#"}],"text":"Definition of immunotype 3\nTo define COVID-19 patients with low or absent immune responses, classified as immunotype 3, the intersection of the bottom 50% of 5 different flow parameters was used: PB as % of B cells, KI67+ as % of non-naïve CD4 T cells, KI67+ as % of non-naïve CD8 T cells, HLA-DR+CD38+ as % of non-naïve CD4 T cells, HLA-DR+CD38+ as % of non-naïve CD8 T cells—graphically displayed in fig. S10."}